Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCiardiello, Fortunato
dc.contributor.authorCiardiello, Davide
dc.contributor.authorMartini, Giulia
dc.contributor.authorNapolitano, Stefania
dc.contributor.authorTabernero Caturla, Josep
dc.contributor.authorCervantes, Andrés
dc.date.accessioned2022-09-12T08:22:48Z
dc.date.available2022-09-12T08:22:48Z
dc.date.issued2022-07
dc.identifier.citationCiardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022 Jul;72(4):372–401.
dc.identifier.issn1542-4863
dc.identifier.urihttp://hdl.handle.net/11351/8137
dc.descriptionImmunotherapy; Metastatic colorectal cancer; Precision medicine
dc.description.abstractColorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause of cancer deaths. Initial clinical presentation as metastatic CRC (mCRC) occurs in approximately 20% of patients. Moreover, up to 50% of patients with localized disease eventually develop metastases. Appropriate clinical management of these patients is still a challenging medical issue. Major efforts have been made to unveil the molecular landscape of mCRC. This has resulted in the identification of several druggable tumor molecular targets with the aim of developing personalized treatments for each patient. This review summarizes the improvements in the clinical management of patients with mCRC in the emerging era of precision medicine. In fact, molecular stratification, on which the current treatment algorithm for mCRC is based, although it does not completely represent the complexity of this disease, has been the first significant step toward clinically informative genetic profiling for implementing more effective therapeutic approaches. This has resulted in a clinically relevant increase in mCRC disease control and patient survival. The next steps in the clinical management of mCRC will be to integrate the comprehensive knowledge of tumor gene alterations, of tumor and microenvironment gene and protein expression profiling, of host immune competence as well as the application of the resulting dynamic changes to a precision medicine-based continuum of care for each patient. This approach could result in the identification of individual prognostic and predictive parameters, which could help the clinician in choosing the most appropriate therapeutic program(s) throughout the entire disease journey for each patient with mCRC.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesCA: A Cancer Journal for Clinicians;72(4)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCòlon - Càncer - Tractament
dc.subjectRecte - Càncer - Tractament
dc.subjectMedicina personalitzada
dc.subject.meshColorectal Neoplasms
dc.subject.mesh/therapy
dc.subject.meshPrecision Medicine
dc.titleClinical management of metastatic colorectal cancer in the era of precision medicine
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3322/caac.21728
dc.subject.decsneoplasias colorrectales
dc.subject.decs/terapia
dc.subject.decsmedicina de precisión
dc.relation.publishversionhttps://doi.org/10.3322/caac.21728
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Ciardiello F, Martini G, Napolitano S] Division of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. [Ciardiello D] Division of Medical Oncology, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. Division of Medical Oncology, IRCCS Foundation Home for the Relief of Suffering, San Giovanni Rotondo, Italy. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Institute of Oncology, University of Vic/Central University of Catalonia, Barcelona, Spain. Oncology Institute of BarcelonaQuironsalud, Biomedical Research Center in Cancer, Barcelona, Spain. [Cervantes A] Medical Oncology Department, Instituto de Investigación Sanitaria Valencia Biomedical Research Institute, University of Valencia, Valencia Spain. Carlos III Institute of Health, Biomedical Research Center in Cancer, Madrid, Spain
dc.identifier.pmid35472088
dc.identifier.wos000787357900001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record